Pharmacokinetics of saquinavir co-administered with cimetidine

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 6, 2002, Pages 1081-1084

  Boffito, Marta ^a   Carriero, Pierluigi ^c   Trentini, Laura ^a   Raiteri, Riccardo ^a   Bonora, Stefano ^a   Sinicco, Alessandro ^a   Reynolds, Helen E ^b   Hoggard, Patrick G ^b   Back, David J ^b   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NONE

Author keywords

Cimetidine; Pharmacokinetics; Protease inhibitors; Saquinavir

Indexed keywords

CIMETIDINE; CYTOCHROME P450; HISTAMINE H2 RECEPTOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL NEPHRITIS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METABOLIC DISORDER; PARESTHESIA; PROTEIN METABOLISM; STEADY STATE; VOLUNTEER;

ADULT; CIMETIDINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; SAQUINAVIR; STATISTICS, NONPARAMETRIC;

EID: 12244313733     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf232     Document Type: Article

References (10)

1. Palella, F. J., Jr, Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satte, G. A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338, 853-60.
2. Piscitelli, S. C. & Gallicano, K. D. (2001). Interactions among drugs for HIV and opportunistic infections. New England Journal of Medicine 344, 984-96.
3. Hoetelmans, R. M. W., Reijers, M. H. E., Weverling, G. J., ten Kate, R. W., Wit, F. W., Mulder, J. W. et al. (1998). The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 12, F111-5.
4. Gatti, G., Di Biagio, A., Casazza, R., De Pascalis, C., Bassetti, M., Cruciali, M. et al. (1999). The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13, 2083-9.
5. Somogy, A. & Gugler, R. (1983). Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics 8, 463-95.
6. 2-receptor antagonists. Clinical Pharmacology and Therapeutics 65, 531-9.
7. Back, D. J., Khoo, S. & Gibbons, S. (2002). The role of therapeutic drug monitoring (TDM) in clinical practice. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract S20, p. 111. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Reynolds, H. E., Tjia, J. F., Gibbons, S. E., Khoo, S. H. & Back, D. J. (2001). Simultaneous determination of four HIV protease inhibitors by HPLC-MS/MS for use in therapeutic drug monitoring service. British Journal of Clinical Pharmacology 52, 481P.
9. Veldkamp, A. I., van Heeswijk, R. P. G., Mulder, J. W., Meenhorst, P. L., Schreij, G., van der Geest, S. et al. (2001). Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1 infected individuals. Journal of Acquired Immune Deficiency Syndromes 27, 344-9.
10. van Heeswijk, R. P. G., Cohen Stuart, J. W. T., Burger, D. M., Beijnen, J. H., Borleffs, J. C. C. & Hoetelmans, R. M. W. on behalf of the CHEESE Study Group. (2002). Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. British Journal of Clinical Pharmacology 53, 211-4.